HOME  |  CONTACT US  |  SUBSCRIBE  |  SUPPORT WLF

Case Detail


In re: Criminal Prosecution of Corporate Officers for Off-Label Promotion
(Regulatory Proceeding)
On October 26, 2010, WLF called on the Food and Drug Administration to abandon its announced plans to seek increased criminal prosecution of company executives for promotional activities in instances where the executives never participated in, encouraged, or had knowledge of the alleged violations. WLF expressed its concerns in a letter to Eric Blumberg, Deputy Chief for Litigation in the FDAís Office of Chief Counsel, in response to recent comments Blumberg made calling for increased criminal prosecution of executive officers in pharmaceutical companies. WLF cautioned that increased criminal prosecution of company executives for promotional activities has the potential to adversely affect the nationís healthcare delivery system by providing industry executives little incentive to continue working in the pharmaceutical sector.
Case Status:
Awaiting FDA response.
More Information and Downloads:
10/26/2010: Download the Letter

  • Welcome to the Washington Legal Foundation
  • 2009 Massachusetts Ave., NW
    Washington, DC 20036
  • info@wlf.org  |  ph. 202-588-0302
    ©2017 WLF All Rights Reserved